| Multiple Sclerosis, Relapsing-Remitting
Mayzent vs Tascenso ODT
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Mayzent vs Tascenso Odt with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTascenso Odt has a higher rate of injection site reactions vs Mayzent based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tascenso Odt but not Mayzent, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mayzent
Tascenso Odt
At A Glance
Oral
Daily
S1P receptor modulator
Oral
Daily
Sphingosine 1-phosphate receptor modulator
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis 2 mg orally once daily (CYP2C9 *1/*1, *1/*2, or *2/*2) or 1 mg orally once daily (CYP2C9 *1/*3 or *2/*3), each initiated with a dose titration regimen; administer tablets whole, do not split, crush, or chew.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Adults and pediatric patients (10 years and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food; pediatric patients (10 years and older) weighing 40 kg or less: 0.25 mg orally once daily, with or without food.
Contraindications
- CYP2C9 *3/*3 genotype
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome without a functioning pacemaker
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within the last 6 months
- History or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome without a functioning pacemaker
- Baseline QTc interval >= 500 msec
- Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs
- Previous hypersensitivity reaction to fingolimod or any excipient (including rash, urticaria, or angioedema)
- Concomitant use with other products containing fingolimod
Adverse Reactions
Most common (>=10%) headache, hypertension, transaminase increased
Serious infections, progressive multifocal leukoencephalopathy, macular edema, bradyarrhythmia and AV conduction delays, liver injury, cutaneous malignancies, posterior reversible encephalopathy syndrome, fetal risk
Postmarketing progressive multifocal leukoencephalopathy
Most common (>=10%) Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, pain in extremity
Serious Bradyarrhythmia, AV blocks, infections, progressive multifocal leukoencephalopathy, macular edema, liver injury, posterior reversible encephalopathy syndrome, fetal risk, malignancies, hypersensitivity reactions
Postmarketing Hemolytic anemia, thrombocytopenia, liver injury, cryptococcal infections, HPV infection, PML, arthralgia, myalgia, PRES, seizures, melanoma, Merkel cell carcinoma, cutaneous T-cell lymphoma, Kaposi's sarcoma, squamous cell carcinoma, hypersensitivity
Pharmacology
Siponimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis is unknown but may involve reduction of lymphocyte migration into the central nervous system.
Fingolimod is metabolized to fingolimod-phosphate, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts, thereby limiting lymphocyte migration into the central nervous system.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mayzent
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Tascenso Odt
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Mayzent
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Tascenso Odt
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Mayzent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Tascenso Odt
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MayzentView full Mayzent profile
Tascenso OdtView full Tascenso Odt profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.